Astellas : News Releases

Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025

7 months ago

- New clinical data across ten accepted abstracts demonstrate significant progress across...

Astellas Announces Top Management Personnel Change

7 months ago

TOKYO, Sep 29, 2025 – Astellas Pharma Inc. (TSE: 4503, President and...

Embracing Communities of Innovation: Massachusetts

7 months ago

Astellas Receives Conditional Approval for IZERVAY, making it the first and only approved treatment for the Suppression of Geographic Atrophy Growth in Japan

7 months ago

TOKYO, Sep 19, 2025 – Astellas Pharma Inc. (TSE: 4503, President and...

PADCEVTM Plus KEYTRUDATM Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery

8 months ago

PADCEV plus KEYTRUDA is the first and only regimen to improve survival...

Posted Financial Results for Q1 YTD/FY2025

9 months ago

Astellas Announces a Partnership with the “Korea Institute of Startup and Entrepreneurship Development”, an Umbrella Organization of a Korean Government Agency, for the Operation of the“Partnership with Global Companies Program”

9 months ago

- Supporting Korean Startups’ Drug Discovery Research and Global Expansion -- First...

Sales of IZERVAY™ (Preliminary Figures)

9 months ago

TOKYO, July 10, 2025 – Astellas Pharma Inc. (TSE: 4503, President and...

Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan

10 months ago

Tokyo, 13 June 2025—Mitsubishi Research Institute, Inc. (“MRI”) and Astellas Pharma Inc...

Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2

11 months ago

- Agreement grants Astellas exclusive worldwide rights (excluding China’s mainland, Hong Kong...

Posted Notice of Convocation of the 20th Term Annual Shareholders Meeting

11 months ago

Shaping the Future with Pompe Patients

11 months ago